Skip to main content
NCBI home page
Frontiers in Molecular Neuroscience logoLink to Frontiers in Molecular Neuroscience
. 2018 Nov 13;11:398. doi: 10.3389/fnmol.2018.00398

Oxytocin, GABA, and TRPV1, the Analgesic Triad?

Abimael Gonzalez-Hernandez 1,*, Alexandre Charlet 2,*
PMCID: PMC6282058  PMID: 30555298

The hypothalamic non-apeptide oxytocin (OT) has several physiological functions, ranging from lactation to social attachment (Gimpl and Fahrenholz, 2001). More recently, a collection of evidence revealed that OT inhibits pain transmission at peripheral (Juif et al., 2013; de Araujo et al., 2014; Tzabazis et al., 2016; González-Hernández et al., 2017), spinal, and supraspinal levels (Eliava et al., 2016; Poisbeau et al., 2018). These data support the prospect that spinal OT could be translated into clinical pain practice (Rash et al., 2014; Eisenach et al., 2015; Condés-Lara et al., 2016). While the receptor(s) and intracellular mechanisms responsible for the OT-induced analgesia are under scrutiny, the main dogma relies on the activation of the OT receptor (OTR).

Indeed, ex vivo studies using capsaicin-sensitive dorsal root ganglia (DRG) neurons, showed that OT induces membrane hyperpolarization and consequently inhibits the nociceptive transmission by Ca2+-dependent mechanisms (Hobo et al., 2012). Additionally, in vivo electrophysiological recordings of the second-order wide-dynamic-range (WDR) neurons and ex vivo patch-clamp as well as behavioral analyses, suggest that OT inhibits the nociceptive input either directly (Eliava et al., 2016), by the enhancement of the GABAergic transmission (Rojas-Piloni et al., 2007; Breton et al., 2008), or by inducing neurosteroids synthesis (Juif et al., 2013). In all cases, the OTR was involved. However, the contribution of the vasopressin V1A receptor (V1AR), for which OT has a physiologically relevant affinity, cannot be ruled out (Schorscher-Petcu et al., 2010; González-Hernández et al., 2014; Manzano-García et al., 2018). Regardless, these findings point to the relevance of GABAergic transmission in the OT-induced analgesia (Figure 1).

Figure 1.

Figure 1

Open in a new tab

Oxytocin and spinal and peripheral analgesia. This schema depicts the proposed mechanism for the oxytocin-mediated peripheral analgesia. Oxytocin could act via either OTR and/or TRPV1 through a three-way path: (i) spinal cord central release, to inhibit WDR neuron activity either directly or via activation of GABAergic neurons; (ii) blood release, through pituitary, to inhibit either the cell body or peripheral nociceptive fibers of DRG neurons; and (iii) skin release, to directly inhibit the excitation of nociceptive fibers. WDR: wide-dynamic-range; DRG: dorsal root ganglia. Adapted from Grinevich and Charlet (2017).

In this context, two recent studies (Nersesyan et al., 2017; Sun et al., 2018) add a new layer to the analgesic mechanisms of the OT, suggesting that apart from the role of OTR and its downstream mechanism, this peptide also interacts (directly or indirectly) with the transient receptor potential vanilloid type1 (TRPV1) at peripheral and spinal levels. Certainly, since this channel physiologically functions as a detector of noxious stimuli (Caterina et al., 2000) and appears to be crucial for the transition from acute to chronic pain (Choi et al., 2016), there is a strong motivation to develop molecules modulating TRPV1 to treat neuropathic pain.

Nersesyan et al. was first to show that aversive behaviors induced by an intracutaneous (i.c.) injection of capsaicin into an animal hindpaw, were reduced in animals concomitantly treated with i.c. OT. One can therefore propose that the OT effect is a result of OTR activation at the peripheral nerve endings (Gong et al., 2015; González-Hernández et al., 2017; Figure 1), challenging the authors hypotheses of direct OT interaction with the TRPV1 channel. Indeed, since OT could modulate the influx of extracellular Ca2+, the role of voltage-gated or ligand-gated channels may play a role, as previously suggested (Sanborn et al., 1998). Based on this reasoning, they showed that OT at μM concentration elicits a Ca2+ influx through TRPV1 expressed in HEK293 cells. Furthermore, the proposed hypothesis was strengthened considering that both the TRPV1 antagonist capsazepine and a TRPV1-specific small interfering RNA (siRNA) abolished the OT-induced Ca2+ influx. These results were confirmed by replicating both the nociceptive DRG neurons isolated from wild-type animals and the modest OT-induced analgesia observed in TRPV1 knock-out mice. Further electrophysiological, planar lipid bilayer, and in silico experiments showed that OT acts as a partial agonist of TRPV1 channels and induces a strong desensitization of these channels, under nociceptive stimulation. This pioneering study strongly suggests that at peripheral level, OT-induced analgesia passes at least in part, through a direct TRPV1 interaction.

To further explore if OT-induced analgesia in neuropathic pain may occur via TRPV1, Sun et al. first confirmed that intrathecal OT diminishes the aversive behavior in neuropathic animals (Miranda-Cárdenas et al., 2006). Interestingly, the cerebrospinal fluid's OT concentration was increased in accordance with the spinal OT increase, measured after a peripheral inflammatory sensitization (Juif et al., 2013). Furthermore, while the spontaneous excitatory postsynaptic currents (sEPSC) recorded in superficial layers of the spinal cord, were not altered by OT, it prevented the capsaicin-induced increase of sEPSC, an effect blocked by the GABAB receptor antagonist saclofen, suggesting a pre-synaptic effect. OT therefore enhanced the spontaneous inhibitory postsynaptic currents (sIPSC) mediated by GABA. These data suggest that OT recruits GABAergic interneurons, which in turn, activate GABAB receptors and consequently inhibit the capsaicin-sensitive neurons. Interestingly, TRPV1 and GABAB receptors were found to be coexpressed in primary nociceptive neurons. Additionally, the TRPV1 spinal cord expression was enhanced in neuropathic rats, an up-expression corrected by intrathecal OT treatment. Accordingly, the OT-induced analgesia was partially reduced in TRPV1 knockout mice. Like the proposal of Nersesyan et al., this study points out that OT-induced analgesia may rely on both GABA release and modulation of TRPV1 activity.

In the past decades, OT has slowly emerged as an important mediator of endogenous analgesia (Poisbeau et al., 2018). Thus, the relevance of oxytocinergic mechanisms implicated in the modulation of nociceptive transmission is under intense scrutiny. These two studies highlight a novel and interesting mechanistic explanation about how OT modulates the nociceptive transmission at the peripheral and spinal levels, under physiological and pathological pain conditions. Several research groups have reported GABAergic enhancement induced by OT at the spinal level, however, Sun et al. demonstrate that, this GABA facilitation engages the function of postsynaptic GABAB receptors, which in turn modulate the TRPV1 function during neuropathic pain. This finding is in line with the observation that GABAB receptors revert the TRPV1 sensitization by noncanonical signaling under pathological pain (Hanack et al., 2015). Additionally, the discovery by Nersesyan et al., that OT could act as an allosteric modulator of TRPV1, highlights the multifaceted actions of OT as a neuromodulator. Certainly, the finding that OT partially blocked the peripheral capsaicin-induced nocifensive behavior, could partly explain why blocking OTR at the peripheral level, only partially reverts the OT antinociceptive effect (González-Hernández et al., 2017).

An intriguing point in Sun et al. study is how exactly, at the spinal level, OT engages the intracellular machinery to modulate the TRPV1 expression. At least two mechanisms can be proposed. The first might be a direct action of OT on TRPV1, as suggested by Nersesyan et al. The second might be that the OT-induced activation of OTR, leads to an intracellular cascade capable of modulating the expression or epigenetic modifications of TRPV1, as suggested by Sun et al. It remains unclear however, how exactly OT modulates the TRPV1 functions and whether it remains true at physiological concentrations. Indeed, while Nersesyan et al. clearly show a direct interaction between OT and TRPV1, neither them nor Sun et al. were able to reveal a strong, behaviorally relevant, OT-mediated TRPV1 modulation. Since OTR was recently involved in functional heterodimers, such as vasopressin or dopamine receptors (Terrillon et al., 2003; Meyer-Lindenberg et al., 2011; De la Mora et al., 2016), the hypothesis of a functional heterodimer formation between OTR and TRPV might be interesting to explore further.

Finally, although the sources of OT and its spinal effects are neuronal and seem to play a role in endogenous analgesia (Eliava et al., 2016), it is more unclear at the peripheral level. Nersesyan et al. suggest that the OT which stimulates TRPV1 is neuronal, we need to keep in mind that other sources could explain the findings reported, such as keratinocytes (Denda et al., 2012), which may release OT upon nociceptive stimulation or self-soothing and consequently induce pain relief (Grinevich and Charlet, 2017; Walker et al., 2017; Figure 1). Certainly, the pleiotropic nature of this peptide, to modulate pain transmission, indicates that differential routes are followed.

In conclusion, a collection of evidence, briefly explained here, suggests that a triad between OT, GABA, and TRPV1 does exist and sheds a light on new mechanisms involved in OT-induced analgesia, which ultimately is much more complex than initially expected.

Author contributions

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgments

This work was supported by the Programa de Apoyo a Proyectos de Investigaión e InnovaciónTecnológica PAPIIT-UNAM Mexico IA203117 (to AG-H); NARSAD Young Investigator Grant 24821, ANR-DFG GR 3619/70 and PICS 07882 grants (to AC).

References

  1. Breton J. D., Veinante P., Uhl-Bronner S., Vergnano A. M., Freund-Mercier M. J., Schlichter R., et al. (2008). Oxytocin-induced antinociception in the spinal cord is mediated by a subpopulation of glutamatergic neurons in lamina I-II which amplify GABAergic inhibition. Mol. Pain 4:19. 10.1186/1744-8069-4-19 [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Caterina M. J., Leffler A., Malmberg A. B., Martin W. J., Trafton J., Petersen-Zeitz K. R., et al. (2000). Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 288, 306–313. 10.1126/science.288.5464.306 [DOI] [PubMed] [Google Scholar]
  3. Choi S. I., Lim J. Y., Yoo S., Kim H., Hwang S. W. (2016). Emerging role of spinal cord TRPV1 in pain exacerbation. Neural Plast 2016:5954890. 10.1155/2016/5954890 [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Condés-Lara M., Zayas-González H., Manzano-García A., Córdova-Quiroz E., Granados-Mortera J., García-Cuevas M., et al. (2016). Successful pain management with epidural oxytocin. CNS Neurosci. Ther. 22, 532–534. 10.1111/cns.12551 [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. de Araujo A. D., Mobli M., Castro J., Harrington A. M., Vetter I., Mettehnthaler M., et al. (2014). Selenoether oxytocin analogues have analgesic properties in a mouse model of chronic abdominal pain. Nat. Commun. 5:3165. 10.1038/ncomms4165 [DOI] [PubMed] [Google Scholar]
  6. de la Mora M. P., Pérez-Carrera D., Crespo-Ramírez M., Tarakanov A., Fuxe K., Borroto-Escuela D. O. (2016). Signaling in dopamine D2 receptor-oxytocin receptor heterocomplexes and its relevance for the anxiolytic effects of dopamine and oxytocin interactions in the amygdala of the rat. Biochim. Biophys. Acta. Mol. Basis Dis. 1862, 2075–2085. 10.1016/j.bbadis.2016.07.004 [DOI] [PubMed] [Google Scholar]
  7. Denda S., Takei K., Kumamoto J., Goto M., Tsutsumi M., Denda M. (2012). Oxytocin is expressed in epidermal keratinocytes and released upon stimulation with adenosine 5′-[γ-thio] triphosphate in vitro. Exp. Dermatol. 21, 535–537. 10.1111/j.1600-0625.2012.01507.x [DOI] [PubMed] [Google Scholar]
  8. Eisenach J. C., Tong C., Curry R. (2015). Phase 1 safety assessment of intrathecal oxytocin. Anesthesiology 122, 407–413. 10.1097/ALN.0000000000000539 [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Eliava M., Melchior M., Knobloch-Bollmann H. S., Wahis J., da Silva Gouveia M., Tang Y., et al. (2016). A new population of parvocellular oxytocin neurons controlling magnocellular neuron activity and inflammatory pain processing. Neuron 89, 1291–1304. 10.1016/j.neuron.2016.01.041 [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Gimpl G., Fahrenholz F. (2001). The oxytocin receptor system: structure, function, and regulation. Physiol. Rev. 81, 629–683. 10.1152/physrev.2001.81.2.629 [DOI] [PubMed] [Google Scholar]
  11. Gong L., Gao F., Li J., Yu X., Ma X., Zheng W., et al. (2015). Oxytocin-induced membrane hyperpolarization in pain-sensitive dorsal root ganglia neurons mediated by Ca2+/nNOS/NO/KATP pathway. Neuroscience 289, 417–428. 10.1016/j.neuroscience.2014.12.058 [DOI] [PubMed] [Google Scholar]
  12. González-Hernández A., Manzano-García A., Martínez-Lorenzana G., Tello-García I. A., Carranza M., Arámburo C., et al. (2017). Peripheral oxytocin receptors inhibit the nociceptive input signal to spinal dorsal horn wide-dynamic-range neurons. Pain 158, 2117–2128. 10.1097/j.pain.0000000000001024 [DOI] [PubMed] [Google Scholar]
  13. González-Hernández A., Rojas-Piloni G., Condés-Lara M. (2014). Oxytocin and analgesia: future trends. Trends Pharmacol. Sci. 35, 549–551. 10.1016/j.tips.2014.09.004 [DOI] [PubMed] [Google Scholar]
  14. Grinevich V., Charlet A. (2017). Oxytocin: pain relief in skin. Pain 158, 2061–2063. 10.1097/j.pain.0000000000001006 [DOI] [PubMed] [Google Scholar]
  15. Hanack C., Moroni M., Lima W. C., Wende H., Kirchner M., Adelfinger L., et al. (2015). GABA blocks pathological but not acute TRPV1 pain signals. Cell 160, 759–770. 10.1016/j.cell.2015.01.022 [DOI] [PubMed] [Google Scholar]
  16. Hobo S., Hayashida K., Eisenach J. C. (2012). Oxytocin inhibits the membrane depolarization-induced increase in intracellular calcium in capsaicin sensitive sensory neurons: a peripheral mechanism of analgesic action. Anesth. Analg. 114, 442–449. 10.1213/ANE.0b013e31823b1bc8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Juif P. E., Breton J. D., Rajalu M., Charlet A., Goumon Y., Poisbeau P. (2013). Long-lasting spinal oxytocin analgesia is ensured by the stimulation of allopregnanolone synthesis which potentiates GABAA receptor-mediated synaptic inhibition. J. Neurosci. 33, 16617–16626. 10.1523/JNEUROSCI.3084-12.2013 [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Manzano-García A., González-Hernández A., Tello-García I. A., Martínez-Lorenzana G., Condés-Lara M. (2018). The role of peripheral vasopressin 1A and oxytocin receptors on the subcutaneous vasopressin antinociceptive effects. Eur. J. Pain 22, 511–526. 10.1002/ejp.1134 [DOI] [PubMed] [Google Scholar]
  19. Meyer-Lindenberg A., Domes G., Kirsch P., Heinrichs M. (2011). Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine. Nat. Rev. Neurosci. 12, 524–538. 10.1038/nrn3044 [DOI] [PubMed] [Google Scholar]
  20. Miranda-Cárdenas Y., Rojas-Piloni G., Martínez-Lorenzana M., Rodríguez-Jiménez J., López-Hidalgo M., Freund-Mercier M. J., et al. (2006). Oxytocin and electrical stimulation of the paraventricular hypothalamic nucleus produce antinociceptive effects that are reversed by an oxytocin antagonist. Pain 122, 182–189. 10.1016/j.pain.2006.01.029 [DOI] [PubMed] [Google Scholar]
  21. Nersesyan Y., Demirkhanyan L., Cabezas-Bratesco D., Oakes V., Kusuda R., Dawson T., et al. (2017). Oxytocin modulates nociception as an agonist of pain-sensing TRPV1. Cell Rep. 21, 1681–1691. 10.1016/j.celrep.2017.10.063 [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Poisbeau P., Grinevich V., Charlet A. (2018). Oxytocin signaling in pain: cellular, circuit, system, and behavioral levels. Curr. Top Behav. Neurosci. 35, 193–211. 10.1007/7854_2018_38 [DOI] [PubMed] [Google Scholar]
  23. Rash J. A., Aguirre-Camacho A., Campbell T. S. (2014). Oxytocin and pain: a systematic review and synthesis of findings. Clin. J. Pain 30, 453–462. 10.1097/AJP.0b013e31829f57df [DOI] [PubMed] [Google Scholar]
  24. Rojas-Piloni G., López-Hidalgo M., Martínez-Lorenzana G., Rodríguez-Jiménez J., Condés-Lara M. (2007). GABA-mediated oxytocinergic inhibition in dorsal horn neurons by hypothalamic paraventricular nucleus stimulation. Brain Res. 1137, 69–77. 10.1016/j.brainres.2006.12.045 [DOI] [PubMed] [Google Scholar]
  25. Sanborn B. M., Dodge K., Monga M., Qian A., Wang W., Yue C. (1998). Molecular mechanisms regulating the effects of oxytocin on myometrial intracellular calcium. Adv. Exp. Med. Biol. 449, 277–286. 10.1007/978-1-4615-4871-3_35 [DOI] [PubMed] [Google Scholar]
  26. Schorscher-Petcu A., Sotocinal S., Ciura S., Dupré A., Ritchie J., Sorge R. E., et al. (2010). Oxytocin-induced analgesia and scratching are mediated by the vasopressin-1A receptor in the mouse. J. Neurosci. 30, 8274–8284. 10.1523/JNEUROSCI.1594-10.2010 [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Sun W., Zhou Q., Ba X., Feng X., Hu X., Cheng X., et al. (2018). Oxytocin relieves neuropathic pain through GABA release and presynaptic TRPV1 inhibition in spinal cord. Front. Mol. Neurosci. 11:248. 10.3389/fnmol.2018.00248 [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Terrillon S., Durroux T., Mouillac B., Breit A., Ayoub M. A., Taulan M., et al. (2003). Oxytocin and vasopressin V1a and V2 receptors form constitutive homo-and heterodimers during biosynthesis. Mol. Endocrinol. 17, 677–691. 10.1210/me.2002-0222 [DOI] [PubMed] [Google Scholar]
  29. Tzabazis A., Mechanic J., Miller J., Klukinov M., Pascual C., Manering N., et al. (2016). Oxytocin receptor: expression in the trigeminal nociceptive system and potential role in the treatment of headache disorders. Cephalalgia 36, 943–950. 10.1177/0333102415618615 [DOI] [PubMed] [Google Scholar]
  30. Walker S. C., Trotter P. D., Swaney W. T., Marshall A., Mcglone F. P. (2017). C-tactile afferents: cutaneous mediators of oxytocin release during affiliative tactile interactions? Neuropeptides 64, 27–38. 10.1016/j.npep.2017.01.001 [DOI] [PubMed] [Google Scholar]

Articles from Frontiers in Molecular Neuroscience are provided here courtesy of Frontiers Media SA

RESOURCES